

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

PROFIT WARNING

This announcement is made by Extrawell Pharmaceutical Holdings Limited (“**Company**”, together with its subsidiaries, “**Group**”) pursuant to Rule 13.09 of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (“**Board**”) of the Company wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group, the Group expects to record a substantial decline in profit for the financial year ended 31 March 2013 when compared with the profit recorded by the Group for the financial year ended 31 March 2012.

Based on the analysis of the information currently available, the substantial decline in profit is mainly attributable to non-cash items, including (i) a non-recurring item of reclassification from translation reserve recorded in the financial year ended 31 March 2012, and (ii) the Group’s share of loss of an associate due to its business start-up costs during the financial year ended 31 March 2013.

The information contained in this announcement is based on the Board’s preliminary assessment of the management accounts for the financial year ended 31 March 2013, which are subject to review and audit by the Company’s auditors. The annual results of the Company for the year ended 31 March 2013 are expected to be published on 28 June 2013.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Director

Hong Kong, 20 June 2013

As at the date of this announcement, the executive directors are Dr. Mao Yumin, Dr. Xie Yi, Dr. Lou Yi and Ms. Wong Sau Kuen and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* *For identification purpose only*